Online inquiry

IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14476MR)

This product GTTS-WQ14476MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14476MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12487MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ803MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ4223MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ8297MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ6497MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ7688MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ1070MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ748MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AAB-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW